Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Sep. 30, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 325,981	$ 143,583
Accounts receivable	671	845
Prepaid expenses	7,276	4,250
Other current assets	1,696	1,782
Marketable securities	126,407	85,020
Short term investments	63,924	86,890
TOTAL CURRENT ASSETS	525,955	322,370
Property and equipment, net	47,786	30,881
Intangible assets, net	14,088	15,363
Long term investments	128,376	137,487
Operating Lease - Right-of-use assets	18,450	16,138
Other assets	272	265
TOTAL ASSETS	734,927	522,504
CURRENT LIABILITIES
Accounts payable	10,037	6,829
Accrued expenses	29,525	5,405
Accrued payroll and benefits	3,648	8,061
Lease liabilities	1,290	1,095
Deferred revenue	150,934	19,291
TOTAL CURRENT LIABILITIES	195,434	40,681
LONG-TERM LIABILITIES
Lease liabilities, net of current portion	22,854	20,044
Deferred revenue, net of current portion	79,749
TOTAL LONG-TERM LIABILITIES	102,603	20,044
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders’ equity:
Common stock, $0.001 par value; 145,000 shares authorized; 104,209 and 102,376 shares issued and outstanding as of June 30, 2021 and September 30, 2020, respectively	197	195
Additional paid-in capital	1,017,949	965,410
Accumulated other comprehensive income	62	18
Accumulated deficit	(581,318)	(503,844)
TOTAL STOCKHOLDERS’ EQUITY	436,890	461,779
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 734,927	$ 522,504